High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.093
+4.09%
--
--
-0.102
+27.3%
--
--
-0.122
+52.38%
Estimates Revision
The market is revising No Change the revenue expectations for Summit Therapeutics Inc. (SMMT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -1.39%.
EPS Estimates for FY2025
Revise Downward
-3.44%
In Past 3 Month
Stock Price
Go Down
-1.39%
In Past 3 Month
11 Analyst Rating
0Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 33.50 USD with a low forecast of 12.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
1 Sell
Strong Buy
0Current: 19.850
Low
12.00
Averages
33.50
High
44.00
0Current: 19.850
Low
12.00
Averages
33.50
High
44.00
Leerink
Underperform
initiated
$12
2025-06-11
Reason
Leerink
Price Target
$12
2025-06-11
initiated
Underperform
Reason
Leerink initiated coverage of Summit Therapeutics with an Underperform rating and $12 price target. Ivonescimab, Summit Therapeutics' VEGF-A/PD-1 bispecific, is a strong product and Summit leadership deserves credit for licensing ex-China rights to the bispecific from Akeso long before the clinical outcomes were clearly compelling, the firm says. However, Leerink does not believe Ivonescimab is the next Keytruda. For the firm, consensus estimates assume an unrealistic share of the current anti-PD(L)1 total addressable market, given the intense and heterogenous competitive landscape, and compared to the PD-(L)1 era, higher threshold for clinical success, regulatory approval, and uptake.
Clear Street
Bill Maughan
initiated
$33
2025-05-22
Reason
Clear Street
Bill Maughan
Price Target
$33
2025-05-22
initiated
Reason
Clear Street analyst Bill Maughan last night initiated coverage of Summit Therapeutics with a Buy rating and $33 price target. Summit is a biotechnology company developing a single asset, ivonescimab, which is "the most exciting pipeline molecule in oncology today," the analyst tells investors in a research note. The firm says ivonescimab has already shown in multiple Phase 3 clinical studies that it can outperform standard-of-care immunotherapy, including the "best-selling global medicine" Keytruda in non-small cell lung cancer.
Clear Street
initiated
$33
2025-05-21
Reason
Clear Street
Price Target
$33
2025-05-21
initiated
Reason
Clear Street initiated coverage of Summit Therapeutics with a Buy rating and $33 price target.
TD Cowen
Tyler Van Buren
Buy
initiated
2025-05-08
Reason
TD Cowen
Tyler Van Buren
Price Target
2025-05-08
initiated
Buy
Reason
TD Cowen analyst Tyler Van Buren initiated coverage of Summit Therapeutics with a Buy rating and no price target. The firm says ivonescimab's "exquisite engagement" of PD-1 and VEGF has translated to superiority versus chemo in second-line EGFRm lung cancer and versus Keytruda in first-line. The firm says this is "unprecedented" and paves a path to capture and expand the growing $50B checkpoint inhibitor market. It cites ivonescimab's potential to demonstrate superior efficacy across solid tumors for the Buy rating.
Jefferies
Kelly Shi
Buy
upgrade
$31 -> $44
2025-04-25
Reason
Jefferies
Kelly Shi
Price Target
$31 -> $44
2025-04-25
upgrade
Buy
Reason
Jefferies analyst Kelly Shi raised the firm's price target on Summit Therapeutics to $44 from $31 and keeps a Buy rating on the shares. Ivonescimab gained approval in China for first-line platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer, the analyst tells investors in a research note, citing a posting on the National Medical Products Administration website. The firm remains "optimistic" and sees "skewed upside" for Summit shares on the HARMONi-2 study. In light of the HARMONi-6 topline data and H-2 approval, Jefferies increased its probability of success on the first-line NSCLC global trials of HARMONi-7 and HARMONi-3. Today's China approval news marks Ivonescimab's second win in NSCLC, a much larger indication than the first approval, the firm says.
Cantor Fitzgerald
Eric Schmidt
Buy
Reiterates
n/a
2025-04-23
Reason
Cantor Fitzgerald
Eric Schmidt
Price Target
n/a
2025-04-23
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Summit Therapeutics Inc (SMMT.O) is -52.02, compared to its 5-year average forward P/E of -15.15. For a more detailed relative valuation and DCF analysis to assess Summit Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-15.15
Current PE
-52.02
Overvalued PE
6.04
Undervalued PE
-36.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-11.01
Current EV/EBITDA
-42.78
Overvalued EV/EBITDA
9.34
Undervalued EV/EBITDA
-31.37
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
340.45
Current PS
1111.53
Overvalued PS
925.45
Undervalued PS
-244.54
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
SMMT News & Events
Events Timeline
(ET)
2025-06-02
13:32:16
Bristol deal takes out 'key' potential buyer of Summit Therapeutics, says Truist
2025-05-30 (ET)
2025-05-30
06:05:48
Summit Therapeutics announces topline results from Phase 3 HARMONi trial
2025-04-25 (ET)
2025-04-25
15:51:20
Citi says buy Summit amid 'significant market confusion'
Sign Up For More Events
Sign Up For More Events
News
Preview
7.0
06-15GlobenewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Preview
7.0
06-12PRnewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Preview
4.0
06-12NASDAQ.COMWhy Summit Therapeutics Stock Tanked Today
Sign Up For More News
People Also Watch
FAQ
What is Summit Therapeutics Inc (SMMT) stock price today?
What is Summit Therapeutics Inc (SMMT)'s business?
What is the price predicton of SMMT Stock?
What is Summit Therapeutics Inc (SMMT)'s revenue for the last quarter?
What is Summit Therapeutics Inc (SMMT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Summit Therapeutics Inc (SMMT)'s fundamentals?
How many employees does Summit Therapeutics Inc (SMMT). have?